SK Biopharm Targets KRW 700 Billion in Annual Sales on Strong Epilepsy Drug Growth
SK Biopharm has set its sights on surpassing KRW 700 billion (approximately $515 million) in annual sales this…
Cenobamate
4 개의 기사가 있습니다.
Epilepsy Drug ‘Cenobamate’ Nears Korea Launch…Dong-A ST applies for approval
The domestic introduction of SK Biopharmaceuticals’ epilepsy drug ‘Cenobamate’ (marketed as ‘Xcopri’ in the U.S.) is underway. Cenobamate,…
Cenobamate Proven Effective for Patients in Korea, China, and Japan
SK Biopharmaceuticals announced that its anti-epileptic drug Cenobamate has demonstrated clinical efficacy for patients in Northeast Asia, paving…
"SK Biopharm's Epilepsy Drug Excels in the U.S."... Growth Expected in the Second Half
SK Biopharm is expected to continue its performance growth in the second half of the year, driven by…